Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard "3+7" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.

Trial Details

NCT ID
NCT07514936
Phase
PHASE3
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • the standard "3+7" regimen
  • Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
Locations (sample)
  • Beijing, None Selected, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the I…
  • Age between 60-75 years at the time of screening, with no gender restrictions;
  • Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;
  • No severe allergic constitution;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →